TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease
Alzheimer's & Dementia · 2025-05 · 21 (5)
DOI: 10.1002/alz.70293 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Alzheimer's & Dementia, online erschienen am 19.05.2025. Verfasst von Stephen Salloway und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized, Plaque, Amyloid. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION The phase 3, open‐label TRAILBLAZER‐ALZ 4 study compared the effect of donanemab versus aducanumab on amyloid plaque (AP) clearance in participants with early symptomatic Alzheimer's disease. METHODS Participants ( n = 148) were randomized 1:1 to receive intravenous donanemab (700 mg every 4 weeks for three doses, then 1400 mg every 4 weeks thereafter) or aducanumab (per label). AP was measured with florbetapir F 18 positron emission tomography. AP clearance was defined as < 24.1 Centiloids. RESULTS At 6, 12, and 18 months, AP clearance was achieved in 37.9%, 70.0%, and 76.8%, respectively, of donanemab‐treated participants versus 1.6%, 24.6%, and 43.1% of aducanumab‐treated participants ( P < 0.001). Median time to clearance was 359 versus 568 days for donanemab‐ versus aducanumab‐treated participants ( P < 0.001). Amyloid‐related imaging abnormality (ARIA)‐edema/effusion occurred in 23.9% and 34.8% of donanemab‐ and aducanumab‐treated participants, respectively. DISCUSSION Donanemab treatment resulted in earlier and greater AP clearance compared to aducanumab. ARIA frequencies were consistent with prior studies. Clinical trial registration: No: NCT05108922, TRAILBLAZER‐ALZ 4 Highlights Here we report the first direct comparator study of two amyloid‐targeting therapies. This was the first investigation of donanemab on biomarker efficacy regardless of tau levels. Donanemab demonstrated superiority over aducanumab in amyloid plaque (AP) clearance. The depth and speed of AP removal did not affect amyloid‐related imaging abnormality risk or incidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
- Butler Hospital, Providence, Rhode Island, USA.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Irvine Clinical Research, Irvine, California, USA.
- The Cognitive and Research Center of New Jersey LLC, Springfield, New Jersey, USA.
ORCID-Profile: Andrew Pain
Förderung
- Eli Lilly and Company
Zitieren
APA
Salloway, S., Pain, A., Lee, E., Papka, M., Ferguson, M. B., Wang, H., Hu, H., Lu, M., Oru, E., Ardayfio, P. A., Hoban, D. B., Collins, E. C., Brooks, D. A., & Sims, J. R. (2025). TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease. Alzheimer's & Dementia, 21(5). https://doi.org/10.1002/alz.70293
Vancouver
Salloway S, Pain A, Lee E, Papka M, Ferguson MB, Wang H, et al. TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease. Alzheimer's & Dementia. 2025;21(5). doi:10.1002/alz.70293
BibTeX
@article{Salloway2025,
author = {Salloway, Stephen and Pain, Andrew and Lee, Elly and Papka, Michelle and Ferguson, Margaret B and Wang, Hong and Hu, Haoyan and Lu, Ming and Oru, Ena and Ardayfio, Paul A and Hoban, Deirdre B and Collins, Emily C and Brooks, Dawn A and Sims, John R},
title = {TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {5},
doi = {10.1002/alz.70293}
}
EUVIMED